Bosentan
- Generic Name
- Bosentan
- Brand Names
- Stayveer, Tracleer
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O6S
- CAS Number
- 147536-97-8
- Unique Ingredient Identifier
- XUL93R30K2
- Background
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
- Indication
Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
- Associated Conditions
- NYHA Functional Class II-IV Pulmonary arterial hypertension, Ocular Inflammation, Ocular bacterial infections
- Associated Therapies
- -
Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia
- Conditions
- Interventions
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2008-10-17
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 20
- Registration Number
- NCT00260819
- Locations
- 🇫🇷
Centre d'Investigation Clinique 9201 Hôpital Européen Georges Pompidou, Paris, France
Treatment of Early Systemic Sclerosis by Bosentan
- Conditions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Rikshospitalet University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00226889
- Locations
- 🇳🇴
Department of rheumatology, Rikshospitalet, Oslo, Norway
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Interventions
- Drug: PlaceboDrug: ClonidineDrug: Nitroglycerin transdermalDrug: Dipyridamole/ Aspirin (Aggrenox)Drug: Desmopressin (DDAVP)Drug: SildenafilDrug: NifedipineDrug: HydralazineDrug: HydrochlorothiazideDrug: BosentanDrug: DiltiazemDrug: EplerenoneDrug: guanfacineDietary Supplement: L-arginineDrug: captoprilDrug: carbidopaDrug: losartanDrug: metoprolol tartrateDrug: nebivolol hydrochlorideDrug: prazosin hydrochlorideDrug: tamsulosin hydrochlorideOther: Head-up tilt.Drug: aliskirenOther: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
- First Posted Date
- 2004-09-20
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- Actelion
- Target Recruit Count
- 185
- Registration Number
- NCT00091715
- Locations
- 🇦🇹
General Hospital of Vienna, Vienna, Austria
🇧🇪UZ Gasthuisberg, Leuven, Belgium
🇨🇦University of Alberta, Edmonton, Alberta, Canada
The Effect of Tracleer® on Male Fertility
- First Posted Date
- 2004-05-04
- Last Posted Date
- 2010-02-12
- Lead Sponsor
- Actelion
- Target Recruit Count
- 22
- Registration Number
- NCT00082186
- Locations
- 🇦🇺
St. Vincent's Hospital, Darlinghurst, Australia
🇺🇸Harbor - UCLA Medical Center, Torrance, California, United States
🇺🇸University of California at San Diego, La Jolla, California, United States
Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2003-10-24
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- Actelion
- Target Recruit Count
- 158
- Registration Number
- NCT00071461
- Locations
- 🇺🇸
Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa city, Iowa, United States
🇺🇸University of Alabama at Birmingham - Pulmonary Division, Birmingham, Alabama, United States
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
- Conditions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Actelion
- Target Recruit Count
- 132
- Registration Number
- NCT00070590
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸UMDNJ, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.